Share ownership Tenaya Therapeutics, Inc.

TNYA

US87990A1060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-07-10 pm EDT			5-day change	1st Jan Change
0.8704 ^USD	+2.40%		+10.61%	+22.33%

Jun. 29	Tenaya Therapeutics, Inc. Announces Management Changes, Effective July 13, 2026	CI
Jun. 29	Tenaya Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective July 13, 2026	CI

Share class: Tenaya Therapeutics, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	216,998,876	215,525,862 ( 99.32 %)	0	99.32 %

Major shareholders: Tenaya Therapeutics, Inc.

Name	Stocks	%	Valuation
Vanguard Capital Management LLC 3.909 %	8,482,288	3.909 %	6 M $
Millennium Management LLC 2.515 %	5,456,666	2.515 %	4 M $
Empery Asset Management LP 1.976 %	4,286,933	1.976 %	3 M $
Citadel Advisors LLC (13f Subfiler) 1.935 %	4,200,000	1.935 %	3 M $
Renaissance Technologies LLC 1.711 %	3,713,761	1.711 %	3 M $
BlackRock Institutional Trust Co. NA 1.63 %	3,536,004	1.63 %	3 M $
Marshall Wace LLP 1.247 %	2,705,390	1.247 %	2 M $
Kalehua Capital Management LLC 0.9217 %	2,000,000	0.9217 %	1 M $
Burkehill Global Management LP 0.9217 %	2,000,000	0.9217 %	1 M $
Geode Capital Management LLC 0.7189 %	1,559,939	0.7189 %	1 M $
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	19.52%
Others	5.3%
Individuals	0.63%
Alphabet, Inc.	0.42%
State Street Corp.	0.33%
Unknown	73.8%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	22.62%
United Kingdom	1.87%
Individuals	0.63%
Austria	0.46%
Switzerland	0.28%
Canada	0.11%
Ireland	0.08%
Spain	0.07%
Hong Kong	0.03%
China	0.02%
Australia	0.02%
Cayman Islands	0.01%
South Korea	0.01%

Based on 1000 largest holdings

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.

Employees

Sector

Biotechnology & Medical Research

More about the company